Bluejay Diagnostics Q1 net loss $2.5M, cash $6.8M; focuses on FDA pathway

Bluejay Diagnostics, Inc.

2023-Q1 EPS reported -$0.12 vs consensus -$1958.40 ▲ beat (+100.0%)

Net loss of $2.5M ($0.12/shr) vs $2.0M ($0.10/shr) in Q1 2022.
Cash and equivalents fell to $6.8M at March 31, 2023 from $10.1M at Dec 31, 2022.
R&D expense rose to $1.4M from $695k, driven by clinical trial and personnel costs.
CEO notes resources aligned with FDA feedback to optimize Symphony IL-6 approval pathway.
No revenue reported; pre-commercial stage diagnostics company.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bluejay Diagnostics, Inc. reported quarter ended March 31, 2023 results: net income $2.5 million, or $0.12 per share, EPS $0.12 per share.

Period: quarter ended March 31, 2023
Net income: $2.5 million, or $0.12 per share
EPS: $0.12 per share
Result: reported results

Exact text from the filing

The net loss was $2.5 million, or $0.12 per share for the three months ended March 31, 2023, compared to $2.0 million, or $0.10 per share, for the comparable period in 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-037951

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.